---
title: "Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288942073.md"
description: "Shanghai Junshi Biosciences (HK:1877) announced the closure of its H share register from June 23 to 26, 2026, to determine eligibility for its 2025 Annual General Meeting. Transfers will be suspended during this period, with the last registration date set for June 22, 2026. The company currently holds a 'Hold' rating with a HK$34.70 price target."
datetime: "2026-06-05T14:44:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288942073.md)
  - [en](https://longbridge.com/en/news/288942073.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288942073.md)
generator: "portal-rs"
---

# Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM

An update from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences has announced the closure of its H share register from 23 June 2026 to 26 June 2026, during which no transfers of H shares will be processed. This measure is to determine which H share investors are entitled to attend and vote at the company’s 2025 annual general meeting scheduled for 26 June 2026.

H shareholders wishing to participate in the AGM must ensure their share transfer documents reach the company’s Hong Kong share registrar by 4:30 p.m. on 22 June 2026, the last registration date. The move clarifies procedural requirements for shareholder participation and reinforces governance transparency for investors in the company’s H shares.

The most recent analyst rating on (HK:1877) stock is a Hold  
 with a HK$34.70 price target.  
 To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock,  
 see the HK:1877 Stock Forecast page. 

**More about Shanghai Junshi Biosciences Co., Ltd. Class H**

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong via H shares, focusing on innovative drug research and development. The company operates under a board structure comprising executive, non-executive and independent non-executive directors, reflecting standard governance practices for a listed mainland Chinese biotech firm.

**Average Trading Volume:** 4,278,441

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$32.94B

Learn more about 1877 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)
- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)

## Related News & Research

- [Junshi Biosciences Shareholders Approve H-Share Buyback Mandate](https://longbridge.com/en/news/293923779.md)
- [Shanghai Junshi Biosciences Calls 2025 AGM and Seeks Mandate for RMB 2.5 Billion Debt Issuance](https://longbridge.com/en/news/288928914.md)
- [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296129742.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**